Literature DB >> 9165065

Activation mechanisms of matrix metalloproteinases.

H Nagase1.   

Abstract

Matrix metalloproteinases (MMPs), also called matrixins, function in the turnover of extracellular matrix components. These enzymes are considered to play important roles in embryo development, morphogenesis and tissue remodeling, and in diseases such as arthritis, periodontitis, glomerulonephritis, atherosclerosis, tissue ulceration, and in cancer cell invasion and metastasis. All MMPs are synthesized as preproenzymes and most of them are secreted from the cells as proenzymes. Thus, the activation of these proenzymes is one of the critical steps that leads to extracellular matrix breakdown. This review describes recent progress made to elucidate the activation mechanisms of pro-matrixins which include extracellular stepwise activation common to most proMMPs, cell surface activation of progelatinase A and procollagenase 3, and intracellular activation of prostromelysin 3 and pro-membrane-type-1 MMP.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9165065

Source DB:  PubMed          Journal:  Biol Chem        ISSN: 1431-6730            Impact factor:   3.915


  210 in total

Review 1.  Extracellular matrix degradation by metalloproteinases and central nervous system diseases.

Authors:  A Lukes; S Mun-Bryce; M Lukes; G A Rosenberg
Journal:  Mol Neurobiol       Date:  1999-06       Impact factor: 5.590

Review 2.  The role of proteinases in angiogenesis, heart development, restenosis, atherosclerosis, myocardial ischemia, and stroke: insights from genetic studies.

Authors:  A Luttun; M Dewerchin; D Collen; P Carmeliet
Journal:  Curr Atheroscler Rep       Date:  2000-09       Impact factor: 5.113

3.  The significance of MMP-1 and MMP-2 in peritoneal disseminated metastasis of gastric cancer.

Authors:  K Mizutani; K Kofuji; K Shirouzu
Journal:  Surg Today       Date:  2000       Impact factor: 2.549

4.  Matrix metalloproteinases and tissue inhibitors of metalloproteinases in synovial fluids from patients with rheumatoid arthritis or osteoarthritis.

Authors:  Y Yoshihara; H Nakamura; K Obata; H Yamada; T Hayakawa; K Fujikawa; Y Okada
Journal:  Ann Rheum Dis       Date:  2000-06       Impact factor: 19.103

5.  Comparative assessment of detergent-based protocols for mouse lung de-cellularization and re-cellularization.

Authors:  John M Wallis; Zachary D Borg; Amanda B Daly; Bin Deng; Bryan A Ballif; Gilman B Allen; Diane M Jaworski; Daniel J Weiss
Journal:  Tissue Eng Part C Methods       Date:  2012-01-26       Impact factor: 3.056

6.  Vascular Dysfunction in Brain Hemorrhage: Translational Pathways to Developing New Treatments from Old Targets.

Authors:  Paul A Lapchak; Qiang Wu
Journal:  J Neurol Neurophysiol       Date:  2011

7.  A rapid lung de-cellularization protocol supports embryonic stem cell differentiation in vitro and following implantation.

Authors:  Todd Jensen; Blair Roszell; Fan Zang; Eric Girard; Adam Matson; Roger Thrall; Diane M Jaworski; Cayla Hatton; Daniel J Weiss; Christine Finck
Journal:  Tissue Eng Part C Methods       Date:  2012-04-17       Impact factor: 3.056

8.  Matrix metalloproteinase-9 deficiency impairs cellular infiltration and bronchial hyperresponsiveness during allergen-induced airway inflammation.

Authors:  Didier D Cataldo; Kurt G Tournoy; Karim Vermaelen; Carine Munaut; Jean-Michel Foidart; Renaud Louis; Agnès Noël; Romain A Pauwels
Journal:  Am J Pathol       Date:  2002-08       Impact factor: 4.307

9.  Mutations in the catalytic domain of human matrix metalloproteinase-1 (MMP-1) that allow for regulated activity through the use of Ca2+.

Authors:  Rudolph D Paladini; Ge Wei; Anirban Kundu; Qiping Zhao; Louis H Bookbinder; Gilbert A Keller; H Michael Shepard; Gregory I Frost
Journal:  J Biol Chem       Date:  2013-01-15       Impact factor: 5.157

10.  Growth factor-dependent activation of the MAPK pathway in human pancreatic cancer: MEK/ERK and p38 MAP kinase interaction in uPA synthesis.

Authors:  Kyung Hee Lee; Myung Soo Hyun; Jae-Ryong Kim
Journal:  Clin Exp Metastasis       Date:  2003       Impact factor: 5.150

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.